Antihyperlipidemic Drugs Market Report 2023-2028: Size, Share, Trends, Analysis & Research
The global antihyperlipidemic drugs market size reached US$ 12.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 16.0 Billion by 2028, exhibiting a growth rate (CAGR) of 4.6% during 2023-2028.
The global antihyperlipidemic drugs market size reached US$ 12.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 16.0 Billion by 2028, exhibiting a growth rate (CAGR) of 4.6% during 2023-2028.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Report Description and Highlights
Report Description
Antihyperlipidemic Drugs Market Trends:
At present, the rising prevalence of hyperlipidemia due to the sedentary lifestyles of individuals
represents one of the key factors supporting the growth of the market. Besides this, the growing
demand for antihyperlipidemic drugs due to the increasing nicotine addiction and high consumption of
fatty food products is offering a positive market outlook. Additionally, there is a rise in the demand for
antihyperlipidemic drugs to treat hypertension and heterozygous hypercholesterolemia among the
masses around the world.
This, coupled with the increasing utilization of antihyperlipidemic drugs to reduce the rates of
hospitalizations and premature deaths, is propelling the growth of the market. Apart from this, the
rising number of genetic and acquired disorders of lipid and lipoprotein metabolism among children
across the globe is offering lucrative growth opportunities to industry investors. Moreover, the
increasing awareness about the harmful impacts of hyperlipidemia among individuals is positively
influencing the market.
Change language